Saratoga Health & Biotechnology Portfolio Fund Class Institutional (SBHIX)
| Fund Assets | 10.10M |
| Expense Ratio | 2.32% |
| Min. Investment | $250 |
| Turnover | 17.00% |
| Dividend (ttm) | 0.25 |
| Dividend Yield | 0.96% |
| Dividend Growth | -75.16% |
| Payout Frequency | Annual |
| Ex-Dividend Date | Dec 10, 2024 |
| Previous Close | 26.60 |
| YTD Return | 17.12% |
| 1-Year Return | 9.05% |
| 5-Year Return | 43.30% |
| 52-Week Low | 21.64 |
| 52-Week High | 27.45 |
| Beta (5Y) | 0.62 |
| Holdings | 32 |
| Inception Date | Jan 27, 2003 |
About SBHIX
Saratoga Health & Biotechnology Portfolio Fund Class I is a mutual fund focused on the healthcare and biotechnology sectors. Its primary objective is to achieve long-term capital growth by investing at least 80% of its assets in equity securities of U.S. and foreign companies that are actively engaged in health care, health products, pharmaceuticals, and biotechnology industries. The fund’s portfolio typically includes a diverse selection of companies ranging from pharmaceutical developers to providers of medical technologies and health services. Notable features include a relatively concentrated portfolio, with around 45% of assets allocated to its top ten holdings, reflecting an emphasis on select high-impact companies in the sector. The fund is intended for investors seeking exposure to the dynamic healthcare and biotech markets, and it has an institutional share class with a minimum investment of $250. Although the fund has historically provided competitive long-term returns, it carries a higher expense ratio compared to peers, reflecting the active management involved in sector-specific research and selection. Saratoga Health & Biotechnology Portfolio Fund Class I plays a specialized role in the financial market, catering to those interested in the growth potential and innovation within the health and biotechnology fields.
Performance
SBHIX had a total return of 9.05% in the past year, including dividends. Since the fund's inception, the average annual return has been 13.09%.
Equivalent Funds
These are funds that follow the same index from the other major fund companies.
Top 10 Holdings
47.72% of assets| Name | Symbol | Weight |
|---|---|---|
| Cardinal Health, Inc. | CAH | 6.23% |
| Cencora, Inc. | COR | 5.42% |
| McKesson Corporation | MCK | 5.34% |
| Amgen Inc. | AMGN | 4.98% |
| United Therapeutics Corporation | UTHR | 4.92% |
| Medpace Holdings, Inc. | MEDP | 4.40% |
| Jazz Pharmaceuticals plc | JAZZ | 4.25% |
| Regeneron Pharmaceuticals, Inc. | REGN | 4.16% |
| Exelixis, Inc. | EXEL | 4.08% |
| Intuitive Surgical, Inc. | ISRG | 3.94% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 10, 2024 | $0.2534 | Dec 11, 2024 |
| Dec 8, 2023 | $1.0202 | Dec 11, 2023 |
| Dec 9, 2022 | $1.2749 | Dec 12, 2022 |
| Dec 10, 2021 | $0.7883 | Dec 13, 2021 |
| Dec 11, 2020 | $2.5794 | Dec 11, 2020 |
| Dec 11, 2019 | $0.9077 | Dec 11, 2019 |